Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Nebulized Budesonide
Nitric Oxide Analyzer
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Asthma diagnosis previously for 6 months
- Past asthma medication without change for previous 6 months
- Increased NO levels and ability to perform maneuver
- ICF signed by parents
Exclusion Criteria:
- Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks
- Hospitalization within 3 months
- Upper or lower airways active infection or cigarette smoke direct exposure
- Use of other asthma medications other than bronchodilators one month prior and during the trial
- Noncompliance
Sites / Locations
- AAADRS Clinical Research Center
Arms of the Study
Arm 1
Arm Type
Active Comparator
Arm Label
A
Arm Description
Nebulized budesonide
Outcomes
Primary Outcome Measures
Exhaled breath nitric oxide pre- to post treatment
Secondary Outcome Measures
Spirometry with peak flow measurements and daily diary scores
Full Information
NCT ID
NCT00522782
First Posted
August 28, 2007
Last Updated
January 22, 2009
Sponsor
AAADRS Clinical Research Center
Collaborators
AstraZeneca
1. Study Identification
Unique Protocol Identification Number
NCT00522782
Brief Title
Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
Official Title
Phase IV Study of the Effect of Nebulized Budesonide on Exhaled Nitric Oxide in Children, Four to Six Years of Age, With Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
January 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
AAADRS Clinical Research Center
Collaborators
AstraZeneca
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.
Detailed Description
Comparisons will be made before and after 2 week therapy of nebulized budesonide in children not on prior anti-inflammatory medications.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Active Comparator
Arm Description
Nebulized budesonide
Intervention Type
Drug
Intervention Name(s)
Nebulized Budesonide
Other Intervention Name(s)
Pulmicort Respules 0.5mg/2ml nebulized
Intervention Description
Pulmicort Respules 0.5mg/2cc
Intervention Type
Device
Intervention Name(s)
Nitric Oxide Analyzer
Other Intervention Name(s)
Niox NO analyzer
Intervention Description
Niox NO analyzer
Primary Outcome Measure Information:
Title
Exhaled breath nitric oxide pre- to post treatment
Time Frame
two weeks
Secondary Outcome Measure Information:
Title
Spirometry with peak flow measurements and daily diary scores
Time Frame
two weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Asthma diagnosis previously for 6 months
Past asthma medication without change for previous 6 months
Increased NO levels and ability to perform maneuver
ICF signed by parents
Exclusion Criteria:
Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks
Hospitalization within 3 months
Upper or lower airways active infection or cigarette smoke direct exposure
Use of other asthma medications other than bronchodilators one month prior and during the trial
Noncompliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel J Lanz, MD
Organizational Affiliation
Principal Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
AAADRS Clinical Research Center
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
We'll reach out to this number within 24 hrs